{
  "docId": "019de074-ac90-73cc-861b-68f2ee02d519",
  "docSlug": "5e6566e4cd37b5a4c67661e229e01a81",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 41 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 41,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "kpi_overview",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a matrix structure to map drug assets (Imfinzi, Tagrisso, Enhertu, etc.) against patient segments and clinical trial names.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ac90-73cc-861b-68f2ee02d519/15",
  "deckHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519",
  "deckJsonHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519.json",
  "deckAnchorHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.24,
        "x": 0.73,
        "y": 0.22
      },
      "kind": "callout",
      "text": "Leading the future of lung cancer treatment",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "125e3705-7a93-448c-9457-95dbb71981e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "Est epi (G7) = estimated epidemiology across G7... Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DxD), Compugen (rilvegostomig).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b26f7e7f-4e1c-475b-ba57-6da8ca24b894",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.7,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "framework",
      "text": "Matrix of patient segments vs. disease drivers",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36cca925-c4ce-4dc1-ad40-ebf2dde55bba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.22,
        "x": 0.74,
        "y": 0.35
      },
      "kind": "list",
      "text": "Tagrisso established TKI backbone in EGFRm; Imfinzi leading IO in unresectable; Advancing best-in-class ADCs; Delivering next-wave bispecifics; Developing novel combinations; Investing in new technologies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c1f332a-1979-4974-b88d-9d53b48cff29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6708e75f-3230-4735-8470-3fc3f5c290b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.19,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "755a8c32-5823-4a1c-bbb1-ed2ae6a1ae90",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "58874372-b0c5-4a3a-badc-41ad243afe3d",
      "evidence": "framework/instance: Matrix of patient segments vs. disease drivers",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "matrix-nxn",
      "slug": null,
      "matchId": "f5485544-642e-450f-ab7b-977712445bf6",
      "evidence": "Grid layout mapping patient segments (columns) to disease drivers (rows)",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 26,
      "from": 10,
      "beatId": "65085a95-2c38-4ee7-a364-a6a8cc62f676",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The slides showcasing progress in Oncology, BioPharmaceuticals, and Rare Disease provide satisfaction and demonstrate the company's growth",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}